141 related articles for article (PubMed ID: 21051589)
21. Rap2 regulates androgen sensitivity in human prostate cancer cells.
Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
23. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
[TBL] [Abstract][Full Text] [Related]
24. Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells.
Zhang J; Hsu B A JC; Kinseth B A MA; Bjeldanes LF; Firestone GL
Cancer; 2003 Dec; 98(11):2511-20. PubMed ID: 14635088
[TBL] [Abstract][Full Text] [Related]
25. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
27. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
28. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
32. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
33. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
34. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
Zoubeidi A; Rocha J; Zouanat FZ; Hamel L; Scarlata E; Aprikian AG; Chevalier S
Mol Cancer Res; 2009 Jan; 7(1):142-55. PubMed ID: 19147545
[TBL] [Abstract][Full Text] [Related]
35. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
Yang L; Egger M; Plattner R; Klocker H; Eder IE
Urology; 2011 Jun; 77(6):1508.e1-7. PubMed ID: 21624609
[TBL] [Abstract][Full Text] [Related]
36. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.
Slupianek A; Yerrum S; Safadi FF; Monroy MA
J Cell Physiol; 2010 Aug; 224(2):369-75. PubMed ID: 20432434
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition.
Oikonomopoulou K; Soosaipillai A; Diamandis EP
Clin Biochem; 2009 Nov; 42(16-17):1705-12. PubMed ID: 19632215
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
